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Abstract 
Objective: There are few published reports concerning the efficacy of oral ibuprofen for 
the treatment of patent ductus arteriosus (PDA) in extremely low birth weight (ELBW) 
infants. Oral ibuprofen was compared to intravenous indomethacin regarding efficacy 
and safety in the treatment of PDA in infants weighting less than 1,000 g at birth. 
Method: This was a retrospective study in a single center. Data on ELBW infants who 
had an echocardiographically confirmed PDA were collected. The infants were treated 
with either intravenous indomethacin or oral ibuprofen. Rate of ductal closure, need 
for additional treatment, drug-related side effects or complications, and mortality were 
compared between the two treatment groups.
Result: 26 infants who received indomethacin and 22 infants who received ibuprofen 
were studied. The overall rate of ductal closure was similar between the two treatments: 
it occurred in 23 of 26 infants (88.5%) treated with indomethacin, and in 18 of 22 
infants (81.8%) treated with ibuprofen (p = 0.40). The rate of surgical ligation (11.5% 
versus 18.2%; p = 0.40) did not differ significantly between the two treatment groups. 
No significant difference was found in post-treatment serum creatinine concentrations 
between the two groups. There were no significant differences regarding additional side 
effects or complications.
Conclusion: In ELBW infants, oral ibuprofen is as efficacious as intravenous indomethacin 
for the treatment of PDA. There were no differences between the two drugs with respect 
to safety. Oral ibuprofen could be used as an alternative agent for the treatment of PDA 
in ELBW infants.
© 2013 Sociedade Brasileira de Pediatria. Published by Elsevier Editora Ltda. 
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Introduction
The incidence of patent ductus arteriosus (PDA) in term 
infants has been estimated to be 57/100,000 live births, 
whereas the incidence of PDA in preterm infants weighing 
501 to 1,500 g has been estimated to be 31%.1,2 In addition, 
55% of infants who weigh 1,000 g or less (extremely low birth 
weight – ELBW) have been described as having symptomatic 
PDA that ultimately requires medical treatment.3,4
Intravenous indomethacin has been the conventional 
pharmacologic treatment for promoting the closure of PDA in 
premature infants. However, concerns remain regarding the 
safety of indomethacin, which affects renal, gastrointestinal, 
and cerebral perfusions, and may lead to complications such 
as transient or permanent renal dysfunction, necrotizing 
enterocolitis, gastrointestinal hemorrhage, and reduced 
cerebral intracellular oxygenation.5-9
In April of 2006, ibuprofen lysine (ibuprofen) was 
introduced as an alternative agent, approved by the U.S. 
Food and Drug Administration, for the closure of PDA in 
premature infants.10 In several randomized controlled 
trials, ibuprofen was equally efficacious as indomethacin 
in the promotion of ductal closure, and had less effects on 
renal, mesenteric, and cerebral perfusions.11-15 However, 
there are few published data on the efficacy of oral 
ibuprofen for PDA treatment targeted to ELBW infants. 
The aim of this study was to compare oral ibuprofen and 
intravenous indomethacin regarding their efficacy and 
safety in the treatment of PDA in infants weighing less than 
1,000 g at birth.
Methods
Patients and study design
This was a retrospective cohort study at the neonatal 
intensive care unit of the Chonnam National University 
Hospital (Gwangju, Korea) between January, 2007 and June, 
2011. The study protocol was approved by the Institutional 
Review Board of the Chonnam National University Hospital. 
The recommendations of the Declaration of Helsinki 
for biomedical research involving human subjects were 
followed. The criteria for enrollment included birth weight 
of 1,000 g or less; echocardiographic evidence of PDA; and 
treatment with either intravenous indomethacin or oral 
ibuprofen. Exclusion criteria were right-to-left shunting; 
major congenital anomalies; intraventricular hemorrhage 
of grade 3 or higher according to the classification by 
Papile et al.16 within the previous 24 hours; life-threatening 
infection; urine output below 1 ml/kg/h during the previous 
8 hours; a serum creatinine concentration of 1.8 mg/dL or 
higher; a blood urea nitrogen concentration greater than 30 
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Comparação de ibuprofeno via oral e indometacina intravenosa no tratamento da 
persistência do canal arterial em neonatos com extremo baixo peso ao nascer
Resumo 
Objetivo: Existem poucos relatórios publicados com relação à eficácia do ibuprofeno via 
oral no tratamento da persistência do canal arterial (PCA) em neonatos com extremo 
baixo peso ao nascer (EBPN). Comparamos o ibuprofeno via oral à indometacina intrave-
nosa no que diz respeito à eficácia e segurança no tratamento de PCA em neonatos com 
peso inferior a 1.000 g ao nascer. 
Método: Este foi um estudo retrospectivo em um único centro. Coletamos dados de neo-
natos com EBPN que tiveram PCA ecocardiograficamente confirmada. Os neonatos foram 
tratados tanto com indometacina intravenosa quanto com ibuprofeno via oral. A taxa de 
fechamento do canal, a necessidade de tratamentos adicionais, os efeitos colaterais ou 
as complicações relacionadas ao medicamento e a mortalidade foram comparados entre 
os dois grupos de tratamento. 
Resultado: Examinamos 26 neonatos que receberam indometacina e 22 que receberam 
ibuprofeno. A taxa geral de fechamento do canal foi semelhante nos dois tratamentos: o 
fechamento do canal ocorreu em 23 dos 26 neonatos (88,5%) no grupo indometacina, e 
em 18 dos 22 neonatos (81,8%) no grupo ibuprofeno (p = 0,40). A taxa de ligadura cirúr-
gica (11,5% em comparação a 18,2%; p = 0,40) não diferiu de forma significativa entre 
os dois grupos de tratamento. Após o tratamento, não foi encontrada nenhuma diferença 
significativa nas concentrações de creatinina sérica entre os dois grupos. Não houve dife-
renças significativas com relação a efeitos colaterais ou complicações adicionais.
Conclusão: Em neonatos com EBPN, o ibuprofeno via oral é tão eficaz quanto a indome-
tacina intravenosa no tratamento da PCA. Não há diferenças entre os medicamentos no 
que diz respeito à segurança. O ibuprofeno via oral poderia ser usado como um agente 
alternativo no tratamento da PCA em neonatos com EBPN.
© 2013 Sociedade Brasileira de Pediatria. Publicado por Elsevier Editora Ltda. 
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mg/dL; a platelet count of 60,000/μL or less; a tendency 
to bleed (defined by the presence of blood in endotracheal 
aspirate, gastric aspirate, stool or urine, and/or oozing 
from puncture sites); and hyperbilirubinemia necessitating 
exchange transfusion. 
Data collected
Clinical data and demographic information were collected 
by reviewing medical records of the enrolled patients. 
The patients were divided into intravenous indomethacin 
and oral ibuprofen groups. Rate of ductal closure, number 
of doses required, need for additional treatments, side 
effects, and complications were compared between the two 
groups. Renal function was evaluated by the assessment of 
urine output, serum creatinine concentrations, and the 
need for furosemide administration. Oliguria was defined 
as a urine output of 1 mL/kg/h or less during a 24-hour 
collection period. Bronchopulmonary dysplasia was defined 
by the need for supplemental oxygen after 28 days of 
life, in association with typical radiographic findings. 
Necrotizing enterocolitis was diagnosed when the clinical 
signs and radiographic evidence of pneumatosis intestinalis, 
hepatobiliary gas, or free intraperitoneal air were present. 
Retinopathy of prematurity was also evaluated. Cranial 
ultrasound examination was performed before and after 
treatment for the assessment of intraventricular hemorrhage 
or periventricular leukomalacia.
Echocardiography
The clinical diagnosis of PDA was confirmed by 
echocardiography (iE33 ultrasound system; Philips Medical 
Systems – Andover, MA, USA) with a 7.5-MHz probe. 
Echocardiographic criteria for PDA included an increased 
left atrial diameter compared with the aortic root (left-
atrium-to-aortic-root ratio ≥ 1.3), visualization of the 
ductus (≥ 1.5 mm), and evidence of left-to-right blood flow 
through the open duct. Color and pulsed wave spectral 
Doppler scans were applied to assess the direction and 
velocity of ductal flow. After the first dose of treatment 
in both groups, an echocardiographic evaluation was 
performed to determine the need for a second or third 
dose. Ductal closure was documented by the absence of 
ductal blood flow on the color Doppler scan. 
Treatment regimens of indomethacin and 
ibuprofen
Intravenous indomethacin (Indocin; Merck – West Point, PA, 
USA) was administered from January, 2007 to April, 2010, 
and oral ibuprofen (Brufen syrup; Sam-il – Seoul, Korea) 
was used between May, 2010 and June, 2011. Indomethacin 
was given in three doses, and the interval varied with 
age. The dosage administered was 0.2 mg/kg as the initial 
dose and 0.1 mg/kg every 24 hours in infants less than 48 
hours old; 0.2 mg/kg as the initial dose, 0.1 mg/kg at the 
12-hour interval, followed by 0.1 mg/kg at 24-hour interval 
in infants over 48 hours old. Ibuprofen was administered 
in three doses of 10 mg/kg, 5 mg/kg, and 5 mg/kg at 
24-hour intervals. Indomethacin (1 mg) was dissolved in 
normal saline solution (0.9%) to a final concentration of 
0.1 mg/mL, and infused over 30 minutes. Ibuprofen was 
administered in a five-fold dilution, using a 5% dextrose 
solution in distilled water through a feeding tube. For all 
patients, ventilator management, fluid therapy, and other 
supportive care were applied by the same guidelines during 
the treatment.
Statistical analysis
A study group of 48 patients should be necessary for the study 
to be able to detect a difference of at least 25 percentage 
points in the closure rate between the oral ibuprofen and 
intravenous indomethacin groups, assuming a closure rate 
of 75 percent with intravenous indomethacin, with a p-value 
of 0.05 and a power of 80%. Continuous data are presented 
as the mean±standard deviation. Comparisons between 
groups were performed using the independent-samples t 
test for continuous variables, and Fisher’s exact test or 
the chi-squared test were used for categorical variables. 
To assess the changes in serum creatinine concentrations 
after treatment, the paired t-test and repeated measures 
ANOVA were performed. The statistical significance was set 
at p < 0.05. All statistical analyses were performed with the 
Statistical Package for Social Sciences (SPSS Inc. – Chicago, 
IL, USA) version 18.0. 
Results
Baseline characteristics
A total of 48 infants were examined: 26 received 
intravenous indomethacin and 22 received oral ibuprofen. 
Indomethacin and ibuprofen groups were similar in their 
baseline characteristics, including gestational age, birth 
weight, gender, delivery method, rate of administration 
of antenatal steroid, ductal diameter, among others 
(Table 1).
Efficacy of treatment
The rate of ductal closure was similar between the two 
treatment groups. Primary ductal closure occurred in 17 
of 26 infants (65.4%) treated with indomethacin, and in 
13 of 22 infants (59.1%) treated with ibuprofen (p = 0.44). 
The number of infants who received a second or third 
pharmacologic treatment included six infants (23.1%) in 
the indomethacin group and five infants (22.7%) in the 
ibuprofen group (p = 0.62). The overall closure rate was 23 
of 26 infants (88.5%) in the indomethacin group, and 18 of 
22 infants (81.8%) in the ibuprofen group (p = 0.40). The 
rate of surgical ligation did not differ significantly between 
the two groups (11.5% versus 18.2%; p = 0.40) (Table 2). 
Safety of treatment
During treatment, three infants (11.5%) developed oliguria 
in the indomethacin group, and one infant (4.5%) in 
the ibuprofen group (p = 0.37). The change of serum 
creatinine concentrations during treatment did not differ 
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significantly between the two groups (p = 0.21). However, 
serum creatinine concentrations increased significantly 
after treatment in each group (indomethacin group, p 
= 0.001; ibuprofen group, p = 0.003). The number of 
furosemide administrations per patient was similar in 
the two groups (0.76 ± 1.39 versus 0.63 ± 0.65; p = 0.66) 
(Table 3). The incidence of intraventricular hemorrhage, 
necrotizing enterocolitis, retinopathy of prematurity, and 
bronchopulmonary dysplasia did not differ significantly 
between the two groups. The survival rate was also similar 
between treatment groups (Table 4).
Discussion
In 1973, Coceani and Olley first reported that E-series 
prostaglandins induced relaxation of isolated strips of 
ductus arteriosus in sheep.17 Subsequent studies have 
demonstrated that PGE1 and PGE2 are the most potent 
endogenous dilators of the ductus arteriosus, although PGI2 
and its metabolites may also play an important vasodilatory 
role. Successful pharmacological closure of PDA with 
indomethacin was first reported in 1976, and indomethacin 
became the conventional pharmacologic treatment for 
PDA in premature infants.18 In April of 2006, ibuprofen 
was introduced as an alternative agent for PDA closure in 
premature infants.10 Several randomized controlled trials 
proved similar efficacies to that of the standard course 
of treatment and limited side effects.11-15 In the Cochrane 
review, which comprised 956 infants from 19 randomized 
controlled trials, there was no significant difference in 
failure rates of PDA closure between infants treated with 
indomethacin and ibuprofen.19 The risk of developing 
necrotizing enterocolitis was reduced with ibuprofen. 
There was less evidence of transient renal insufficiency in 
infants who received ibuprofen compared to indomethacin. 
No other important differences were observed for common 
neonatal morbidities. 
Table 1 Baseline characteristics of the indomethacin and ibuprofen groups.
 Indomethacin group (n = 26) Ibuprofen group (n = 22) p-value
Gestational age (weeks) 27.0±1.3 26.7±1.0 0.28
Birth weight (g) 869.2±90.8 814.5±117.0 0.08
Male/female 6/20 9/13 0.15
Antenatal steroid (%) 16 (61.5) 16 (72.7) 0.30
Delivery by cesarean section (%) 21 (80.8) 17 (77.3) 0.52
Apgar score   
1 min 3.42±1.39 2.77±1.41 0.11
5 min 5.50±1.55 5.27±1.95 0.65
Surfactant use   
1 dose 25 17 0.62
≥ 2 doses 1 5 0.62
Inspired O2, FiO2 (%)* 25.0±3.9 25.8±7.9 0.67
HFV  3 0 0.15
Ventilator (days) 22.8±14.4 28.0±17.0 0.26
Inotropics 1st 48 hours (%) 18 (69.2) 14 (63.6) 0.45
Ductal diameter (mm) 2.10±0.72 1.90±0.42 0.25
Age at drug administration (days) 5.34±6.02 5.36±3.69 0.99
FiO2, fraction of inspired oxygen; HFV, high-frequency oscillatory ventilation.
*Values for the day of treatment initiation.
Table 2 Efficacy of treatment for the indomethacin and ibuprofen groups.
 Indomethacin group (n = 26) Ibuprofen group (n = 22) p-value
Primary closure ratea (%) 17 (65.4) 13 (59.1) 0.44
Secondary closure rateb (%) 6 (23.1) 5 (22.7) 0.62
Overall closure rate (%) 23 (88.5) 18 (81.8) 0.40
Surgical ligation rate (%) 3 (11.5) 4 (18.2) 0.40
aDuctal closure rate after the first drug administration.
bDuctal closure rate after the second or third drug administration in patients whose duct failed to close after the first drug 
administration.
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As mentioned above, most of the previous studies 
demonstrate that treatment with indomethacin and 
ibuprofen have had similar effects to the present results 
regarding PDA closure. However, there are few published 
reports on the efficacy and safety of ibuprofen for PDA 
confined to ELBW infants. Van Overmeire et al.11 studied 
the efficacy of indomethacin and ibuprofen administered 
to infants born at 24 to 32 weeks of gestation. They 
reported that the closure rates were 66% and 70% after 
the first course of treatment with indomethacin and 
ibuprofen, respectively. Lago et al.13 enrolled infants born 
at 23 to 34 weeks of gestation. The efficacy after the first 
course of treatment was 69% and 73% for indomethacin and 
ibuprofen, respectively. These two studies established that 
infants of lower gestational age (28 weeks or less) had a 
lower pharmacological closure rate and underwent surgical 
ligation more frequently; however, there was no difference 
in the efficacy between the drugs within each category of 
gestational age. In the present study, the primary closure 
rate (indomethacin group, 65%; ibuprofen group, 59%) 
was lower than that reported in other studies involving 
larger premature infants, most likely because the enrolled 
patients were solely ELBW infants. However, the overall 
closure rates (indomethacin group, 88.5%; ibuprofen group, 
81.8%) did not demonstrate a difference when compared 
to other studies. There was no statistically significant 
difference in the efficacy between the two drugs. The 
present study confirms that oral ibuprofen is as effective as 
intravenous indomethacin for the treatment of PDA, even 
in ELBW infants. 
Several studies involving oral ibuprofen for ductal closure 
have been published.20-22 Chotigeat et al.20 reported PDA 
closure in seven of 15 premature infants (35 weeks or less) 
given oral ibuprofen and in ten of 15 premature infants 
given intravenous indomethacin (p = 0.46). Fakhraee et al.21 
reported that PDA was closed in all of the 18 premature 
infants (34 weeks or less) given oral ibuprofen, and in 15 of 
the 18 premature infants given oral indomethacin (p > 0.05). 
Aly et al.,22 in a randomized pilot study, reported that PDA 
was closed in seven of nine premature infants (35 weeks or 
less) given oral ibuprofen, and in ten of 12 premature infants 
given intravenous indomethacin (p = 0.75). Gokmen et 
al.,23 in a prospective randomized study, reported that oral 
ibuprofen was more effective than intravenous ibuprofen 
(84.6% versus 62%) for ductal closure in preterm infants (32 
weeks or less, 1,500 g or less). The authors concluded that 
oral ibuprofen might constitute an alternative agent for 
the treatment of PDA. In addition, Sosenko et al.24 recently 
studied the timing of ibuprofen treatment for PDA. They 
reported that patients with mild signs of PDA did not benefit 
from early PDA treatment compared with treatment delayed 
until the onset of clear hemodynamic signs.
There are not enough reports on the pharmacokinetics 
of oral ibuprofen in premature infants. Raju et al.25 
reported that ibuprofen was absorbed rapidly after oral 
administration, and peak concentrations in plasma were 
Table 3 Effects on renal function in the indomethacin and ibuprofen groups.
 Indomethacin group (n = 26) Ibuprofen group (n = 22) p-value
Occurrence of oliguriaa (%)  3 (11.5) 1 (4.5) 0.37
Serum creatinine (mg/dL)   
Before treatment 0.84±0.34 0.64±0.41 0.21c
After treatment 1.21±0.44b 1.11±0.72b 
Furosemided 0.76±1.39 0.63±0.65 0.66
aOliguria was defined as a urine output of 1 ml/kg/h or less during 24 hours. 
bSerum creatinine concentrations were increased significantly after treatment in each group (indomethacin group, p = 0.001; 
ibuprofen group, p = 0.003). 
cThere were no statistically significant differences between the two groups (p = 0.21).
dMean number of administrations of furosemide per patient.
Table 4 Complications in the indomethacin and ibuprofen groups.
 Indomethacin group (n = 26) Ibuprofen group (n = 22) p-value
IVH (%) 6 (23.1) 6 (27.3) 0.49
NEC (%) 1 (3.8) 2 (9.1) 0.43
ROP (%) 16 (61.5) 16 (72.7) 0.41
BPD (%) 24 (92.3) 18 (81.8) 0.39
Death (%) 4 (15.4) 4 (18.1) 0.54
BPD, bronchopulmonary dysplasia; IVH, intraventricular hemorrhage; NEC, necrotizing enterocolitis; ROP, retinopathy of prematurity.
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observed after 1 to 2 hours in premature infants. Recently, 
Barzilay et al.26 evaluated the pharmacokinetic profile 
of oral ibuprofen in premature infants, showing that oral 
ibuprofen levels peaked 8 hours after administration, and 
remained relatively stable for at least 24 hours. Several 
trials regarding the pharmacokinetics of oral ibuprofen 
in premature infants revealed a wide interindividual 
variability for plasma concentrations, elimination half-life, 
and area under the plasma concentration-time curve.26-28 
The slower absorption of oral ibuprofen, compared with 
the intravenous route, and the longer half-life probably 
prolonged the time of contact with the ductus, leading to 
a higher responsiveness. In addition, oral ibuprofen has the 
advantages of easy availability, simple administration, and 
reduced cost. In Korea, the use of intravenous indomethacin 
was suspended in April, 2010, and ibuprofen has been solely 
used as an alternative agent to promote ductal closure. The 
authors have used oral ibuprofen instead of intravenous 
ibuprofen due to the difficulties in obtaining the latter, as 
well as its higher cost.
Previous studies concluded that indomethacin treatment 
improves PDA closure, but is associated with increased 
renal side effects and more severe complications, such 
as necrotizing enterocolitis, gastrointestinal hemorrhage, 
and reduced cerebral intracellular oxygenation.5-9 In the 
present study, though not significantly different, more 
infants treated with indomethacin presented a tendency to 
develop oliguria than infants treated with ibuprofen. Of the 
two cyclooxygenase isoenzymes (COX-1 and COX-2), COX-1 
appears to be primarily involved in basal physiological 
processes of the kidney.29 Although both isoenzymes are 
inhibited by ibuprofen and indomethacin, indomethacin is 
more potent against COX-1.30
The present study has several limitations. The major 
limitation is its retrospective design, and thus the present 
results may be vulnerable to confounding errors and bias. 
Second, this study may not have had sufficient statistical 
power for this outcome, due to the relatively small sample 
size. Future research should include increased sample size 
to increase the statistical power. A prospective randomized 
study based on a larger population is necessary for further 
conclusive data.
In summary, the present data indicate that oral ibuprofen 
is as efficacious as intravenous indomethacin for the 
treatment of PDA in ELBW infants. There are no differences 
between the two drugs with regards to safety. Oral 
ibuprofen could be used as an alternative agent for the 
treatment of PDA in ELBW infants.
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